- About us
- Join Putnam
NSCLC represented a core indication for the client, including a near term focus on developing its pipeline asset for the KRAS G12C segment. The client required a comprehensive view of the patient opportunity by granular sub-segments through a sophisticated model covering various dynamics including competitive dynamics and Tx sequencing.
Stocks-and-flow approach was used to track and flow patients longitudinally as they progress / exit from successive lines of therapy based on Kaplan-Meir Curves while maintaining treatment history.
The model covered nuances unique to the disease:
Comprehensive secondary search was carried out to source model inputs such as SEER*stat, cbiportal, clinical trials, published literature and real-world data (provided by client).
We delivered on the model allowing the client to capture granular patient flow in NSCLC by segment along with reliable and credible estimates of inflows and prevalence in various patient settings. The model was also useful in understanding potential future disruption due to innovation and introduction of new Tx.
Putnam PHMR’s client needed a detailed description of multiple myeloma treatment patterns and resource utilization in Japanese patients...
An emerging biotech sought Putnam’s guidance to design and execute the global commercialization of their asset for a rare oncology indication.
A global, top-10 pharma client sought Putnam’s guidance on developing a lean launch strategy for a novel cell therapy in oncology.